Form 8-K · Current Report · Filed 2025-11-06
Cidara Therapeutics Reports Q3 2025 Financial Results and Corporate Update
Cidara Therapeutics, Inc. reported financial results for the third quarter of 2025 and provided updates on its non-vaccine influenza preventative therapeutic, CD388. The company's cash balance increased significantly to $476.5 million. Key highlights include the enrollment and dosing of the first patients in the Phase 3 ANCHOR study, a BARDA award for CD388, and the FDA granting Breakthrough Therapy designation to CD388. The company expects to achieve target enrollment of 6,000 participants by December 2025. Acquired in-process R&D expenses amounted to $45.0 million for the quarter, related to a milestone payment under the Janssen License Agreement.
- Filer
- Cidara Therapeutics Inc. CDTX · NASDAQ
- Filed
- Accession
- 0001610618-25-000094
- CIK
- 0001610618
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$97.64
Next session
+6.9%
Since filing
+126.7%
Latest close
$221.38
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from CDTX reporting the same item, with the next session's move:
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Never miss another CDTX filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.